Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Language
Publication year range
1.
Rev Esp Enferm Dig ; 115(3): 146, 2023 03.
Article in English | MEDLINE | ID: mdl-35791787

ABSTRACT

Metastasic Crohn disease (MCD) is the most uncommon cutaneous manifestation of Crohn disease. The actual incidence is not clear. There are fewer than 200 cases described in the literature. We report a case of 21 years-old girl that came to our emergency care with large exudative ulcers in the inguinal folds, the vulva, the perianal region and the popliteal fossae. Histopathological examination of the ulcers revealed a non-caseating granulomatous inflammation with abundant multinucleated giant cells and intense lymphocytic infiltrate. Colonoscopy, contrast study of the small bowel and video capsule endoscopy were carried out without evidence of digestive disease. High potency topical steroids (betamethasone 0,5mg/gr twice daily) and 300mg intravenous Infliximab were initiated as the initial line therapy and the ulcers began to heal. We report this case to highlight the presence of cutaneous ulcers without intestinal disease in a young non-pediatric woman as the unique manifestation of the disease.


Subject(s)
Crohn Disease , Female , Humans , Young Adult , Adult , Crohn Disease/drug therapy , Ulcer/etiology , Ulcer/drug therapy , Infliximab/therapeutic use , Colonoscopy , Inflammation , Chronic Disease
3.
Quant Imaging Med Surg ; 12(4): 2356-2367, 2022 Apr.
Article in English | MEDLINE | ID: mdl-35371947

ABSTRACT

Background: Validated rectal cancer staging groups T3 tumours in a single stage and depth of mesorectal invasion subclassification is not standard practice. Our aim is to report concordance between magnetic resonance imaging (MRI) and endorectal ultrasound (ERUS) for preoperative staging of T3 rectal tumours using a 5-mm cut-off point and possible survival implications. Methods: Prospective cohort study including patients staged preoperatively as cT3 by ERUS or magnetic resonance imaging. The maximum depth of penetration beyond the outer longitudinal muscle layer was measured according to a 5-mm cut-off point. Concordance rate and Kappa coefficient were calculated for both techniques. Primary end-points were disease free survival and overall survival (OS) for both groups. Results: A total of 97 patients were included. Disease-free survival in depth of mesorectal invasion ≤5 and >5 mm measured by ERUS was 130.80 (119.20-142.30) vs. 88.38 (56.13-120.64) months (P=0.020), respectively, and 129.90 (117.90-141.90) vs. 93.60 (64.50-122.70) months (P=0.045) when measured by magnetic resonance imaging. Depth of mesorectal invasion ≤5 mm measured by ERUS and MRI was a prognostic factor for both OS [ERUS P=0.009; MRI P=0.019] and DFS (ERUS P=0.026; MRI P=0.054) after Cox regression analysis. Conclusions: T3 subclassification above and below 5mm is feasible by ERUS, shows good concordance with validated magnetic resonance and can easily be incorporated into the diagnostic workup for these patients with possible survival implications.

SELECTION OF CITATIONS
SEARCH DETAIL
...